Science Explorer Back to mapMap
Discussion
Company · Bedminster · United States

QRx Pharma (United States)

qrxpharma.comROR OpenAlex
Research works
17
▲ 246% vs 2018-21
Citations
185
11.1 per fractional work
Top-10% rate
8.1%
all institutions 10.0%
Open access
24%
world 40%
International
19%
world 18%
QRx Pharma (United States)

Not ranked overall: QRx Pharma (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does QRx Pharma (United States) work in?

In all years, 66% of research at QRx Pharma (United States) is in Health Sciences, 12% in Social Sciences. Its largest fields are Medicine (64%), Decision Sciences (10%), Biochemistry, Genetics and Molecular Biology (7%). It does 2.0× the world's share of Health Sciences.

Health Sciences: 11 fractional works · 66.2% of its workMedicine: 11 fractional works · 64.1% of its workSurgery: 3 fractional works · 15.7% of its workAnesthesiology and Pain Medicine: 2 fractional works · 14.0% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 8.9% of its workPulmonary and Respiratory Medicine: 1 fractional works · 7.3% of its workPsychiatry and Mental health: 1 fractional works · 5.0% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 3.6% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 3.2% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 2.0% of its workImmunology and Allergy: 0 fractional works · 1.3% of its workNephrology: 0 fractional works · 1.2% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 0.5% of its workNeurology: 0 fractional works · 0.5% of its workPhysiology: 0 fractional works · 0.5% of its workOncology: 0 fractional works · 0.2% of its workNursing: 0 fractional works · 2.2% of its workNutrition and Dietetics: 0 fractional works · 2.2% of its workSocial Sciences: 2 fractional works · 12.5% of its workDecision Sciences: 2 fractional works · 9.8% of its workInformation Systems and Management: 1 fractional works · 8.0% of its workManagement Science and Operations Research: 0 fractional works · 1.9% of its workSocial Sciences: 0 fractional works · 2.0% of its workAnthropology: 0 fractional works · 2.0% of its workBusiness, Management and Accounting: 0 fractional works · 0.7% of its workManagement Information Systems: 0 fractional works · 0.7% of its workLife Sciences: 2 fractional works · 12.4% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 7.4% of its workMolecular Biology: 1 fractional works · 4.0% of its workGenetics: 0 fractional works · 2.0% of its workBiophysics: 0 fractional works · 1.0% of its workCancer Research: 0 fractional works · 0.4% of its workNeuroscience: 0 fractional works · 2.4% of its workCognitive Neuroscience: 0 fractional works · 2.0% of its workNeurology: 0 fractional works · 0.4% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 2.0% of its workPharmacology: 0 fractional works · 2.0% of its workImmunology and Microbiology: 0 fractional works · 0.7% of its workImmunology: 0 fractional works · 0.7% of its workPhysical Sciences: 1 fractional works · 8.9% of its workChemistry: 1 fractional works · 5.2% of its workAnalytical Chemistry: 1 fractional works · 5.0% of its workSpectroscopy: 0 fractional works · 0.3% of its workEngineering: 0 fractional works · 2.0% of its workControl and Systems Engineering: 0 fractional works · 1.3% of its workBiomedical Engineering: 0 fractional works · 0.7% of its workComputer Science: 0 fractional works · 1.7% of its workComputer Networks and Communications: 0 fractional works · 1.0% of its workComputational Theory and Mathematics: 0 fractional works · 0.7% of its workALL ITS WORKQRx Pharma(United States)17fractional works, all years
Life Sciences12%Physical Sciences9%Health Sciences66%Social Sciences12%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Medicine1164.1%
    2. Nursing02.2%
    1. Decision Sciences29.8%
    2. Social Sciences02.0%
    3. Business, Management and Accounting00.7%
    1. Biochemistry, Genetics and Molecular Biology17.4%
    2. Neuroscience02.4%
    3. Pharmacology, Toxicology and Pharmaceutics02.0%
    4. Immunology and Microbiology00.7%
    1. Chemistry15.2%
    2. Engineering02.0%
    3. Computer Science01.7%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 6.77× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 3.74× its world share, 0 worksImmunology and Micro…Neuroscience: 1.39× its world share, 0 worksNeuroscienceComputer Science: 0.73× its world share, 0 worksComputer ScienceMedicine: 2.57× its world share, 2 worksMedicineDecision Sciences: 2.92× its world share, 0 worksDecision Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 6.8×. Every wedge is a field page.

All 6 fields, with their numbers
  1. Biochemistry, Genetics and Molecular Biology6.77×1 works
  2. Immunology and Microbiology3.74×0 works
  3. Decision Sciences2.92×0 works
  4. Medicine2.57×2 works
  5. Neuroscience1.39×0 works
  6. Computer Science0.73×0 works

Who are the top researchers at QRx Pharma (United States)?

Ranked on the quality score, Patricia T. Richards lead among researchers whose main affiliation is QRx Pharma (United States).

  1. 1 Patricia T. Richards United States · #2,614,846 worldwide 1.2k citations · 36 works
All ranked researchers at QRx Pharma (United States)

What are the most cited papers from QRx Pharma (United States)?

The most cited paper from QRx Pharma (United States) is "Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial" (Deepak L. Bhatt, Philippe Gabríel Steg, Eliot A. Brinton et al., 2017), with 183 citations. Next come "Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol" (127) and "High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk" (121).

Most cited papers
#PaperReleasedCitations
1 Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial Deepak L. Bhatt, Philippe Gabríel Steg, Eliot A. Brinton et al. · Clinical Cardiology Open access Mar 2017 183
2 Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol Gregory A. Nichols, Sephy Philip, Kristi Reynolds et al. · Diabetes Obesity and Metabolism Open access 18 Sep 2018 127
3 High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk Peter Paul Toth, Craig B. Granowitz, MICHAEL L. HULL et al. · Journal of the American Heart Association Open access 7 Aug 2018 121
4 Real-time on-line blend uniformity monitoring using near-infrared reflectance spectrometry: A noninvasive off-line calibration approach Yusuf Sulub, Busolo Wabuyele, Paul Gargiulo et al. · Journal of Pharmaceutical and Biomedical Analysis 15 Oct 2008 77
5 Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects Rene A. Braeckman, William G. Stirtan, Paresh N. Soni · Clinical Pharmacology in Drug Development Open access 11 Oct 2013 55
All 23 most cited papers, with filters and sorting

Which research topics does QRx Pharma (United States) publish most on?

By volume in 2022-now: Epilepsy research and treatment, RNA Interference and Gene Delivery, Virus-based gene therapy research and CRISPR and Genetic Engineering.

Epilepsy research and tr…1Epilepsy research and treatment: 1 fractional worksRNA Interference and Gen…0RNA Interference and Gene Delivery: 0 fractional worksVirus-based gene therapy…0Virus-based gene therapy research: 0 fractional worksCRISPR and Genetic Engineering: 0 fractional worksAllergic Rhinitis and Sensitization: 0 fractional worksOcular Surface and Conta…0Ocular Surface and Contact Lens: 0 fractional worksCaching and Content Delivery: 0 fractional worksAsthma and respiratory diseases: 0 fractional worksAdvanced Database Systems and Queries: 0 fractional worksData Quality and Management: 0 fractional works
Psychiatry and Mental healthMolecular BiologyGeneticsImmunology and Allergy4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Epilepsy research and treatment Psychiatry and Mental health 1 works
  2. 2 RNA Interference and Gene Delivery Molecular Biology 0 works
  3. 3 Virus-based gene therapy research Genetics 0 works
  4. 4 CRISPR and Genetic Engineering Molecular Biology 0 works
  5. 5 Allergic Rhinitis and Sensitization Immunology and Allergy 0 works
  6. 6 Ocular Surface and Contact Lens Public Health, Environmental and Occupational Health 0 works
  7. 7 Caching and Content Delivery Computer Networks and Communications 0 works
  8. 8 Asthma and respiratory diseases Physiology 0 works
  9. 9 Advanced Database Systems and Queries Computer Networks and Communications 0 works
  10. 10 Data Quality and Management Management Science and Operations Research 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available24.2%not open75.8%

World: 40% of research is openly available.

with international co-authors19.4%domestic only80.6%

World: 18% is written across borders.

How has QRx Pharma (United States)'s research output changed?

Output in 2022-2025 was 246% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is QRx Pharma (United States) as a percentage of every work published that year, 0.000015% in 2024.

still counting0.00010%0.00020%QRx Pharma (United States)0.000020% in 202519801990200020102020

Fractional works of QRx Pharma (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Bedminster

All research institutions in Bedminster

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about QRx Pharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.